The clinical experience of compassionate use program for avapritinib: implications for drug positioning in the therapeutic scenario of systemic mastocytosis

The clinical experience of compassionate use program for avapritinib: implications for drug positioning in the therapeutic scenario of systemic mastocytosis

In systemic mastocytosis, cytoreductive treatment is indicated for advanced systemic mastocytosis (AdvSM) variants. The treatment scenario is rapidly diversifying especially with the introduction of KIT tyrosine kinase inhibitors. Avapritinib is a second-generation potent and selective inhibitor of...

Full description

Bibliographic Details
Main Authors: Francesco Mannelli, Francesca Crupi, Roberta Zanotti, Livio Pagano, Davide Rapezzi, Ilaria Tanasi, Marianna Criscuolo, Massimiliano Bonifacio, Alberto Fresa, Paola Guglielmelli, Alessandro M. Vannucchi
Format: Article
Language:English
Published: SAGE Publishing 2023-10-01
Series:Therapeutic Advances in Hematology
Online Access:https://doi.org/10.1177/20406207231205643

Internet

https://doi.org/10.1177/20406207231205643

Similar Items